Developer docs
API playgroundTry for free, no card

Search company profiles

Florida Pharmaceutical Products

Full company profile

uuid000q45x

Namestring
Florida Pharmaceutical Products
Legal namestring
Florida Pharmaceutical Products, LLC
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Florida Pharmaceutical Products, LLC (FPP) is a Boca Raton, Florida-based generic pharmaceutical company that develops, in-licenses, markets, and distributes FDA-approved generic prescription medications across 10+ therapeutic categories including oncology (Abiraterone, Exemestane, Mercaptopurine), antivirals (Tenofovir, Entecavir, Valganciclovir, Acyclovir), ALS (Riluzole), cardiovascular and ophthalmic agents, anticonvulsants (Lacosamide), and diabetes (Glimepiride). The company operates through three business models: organic ANDA development, in-licensing of ANDAs from international manufacturers, and asset acquisition — exemplified by the May 2020 purchase of Quinn Pharmaceuticals label assets. Its product surface is anchored by the FPP Label and the acquired Quinn Label product lines, with supply chain and manufacturing executed via 3PL partners and DSCSA-compliant packaging/labeling.

FPP was founded by Larry Runsdorf and is currently led by President Larry J. Lapila (a 35-year industry veteran). In May 2019 the company was acquired by Contract Pharmacal Corp. (CPC), a family-owned Hauppauge, NY-based pharmaceutical manufacturer with approximately 1,500 employees, and FPP is also identified as part of Indoco Remedies Ltd.'s group of companies. Capital and manufacturing capacity from CPC, combined with strategic alliances to Bluepharma (Portugal), Qilu Pharmaceutical (China), Inventia Healthcare (India), Standard Chem. & Pharm. (Taiwan), ONConcept (Europe), and Impopharma (Canada), provide FPP with cross-continental sourcing for both development-stage and FDA-approved generic candidates. The company filed its first internally developed ANDA in February 2020 (~$100M market opportunity per IQVIA) and achieved FDA approval of Abiraterone Acetate 500mg Tabs in September 2023 (generic of Zytiga, current generic market of $175M+).

FPP runs a sales-led, B2B distribution model targeting retail pharmacies, healthcare providers, and institutional buyers across the US market, with pricing executed through multi-year negotiated contracts and subject to federal/state government pricing programs. Revenue is generated through product sales plus licensing/royalty arrangements with manufacturing partners, with FPP providing order-to-cash services including chargeback processing, rebates, and gross-to-net accounting under tight DSCSA-compliance governance. The customer base is US-only and distributed across the healthcare system, with no public revenue disclosure available in the source material.

Short descriptiontext

Florida Pharmaceutical Products is a Boca Raton, FL-based generic pharmaceutical developer and distributor that in-licenses, develops, and markets FDA-approved generic prescription drugs across 10-plus therapeutic areas to US retail pharmacies, healthcare providers, and institutional buyers via a sales-led B2B distribution model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoca Raton, United States
HQ citystring
Boca Raton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, prescription medications, ANDA development, pharmaceutical distribution, generic drug licensing
Industry4 codes
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Generic Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Generic Pharmaceutical Sales
TypeLicensing Royalties
Description

FPP generates revenue through the development, licensing, sales, marketing, and distribution of generic pharmaceutical products. Revenue is derived from product sales to healthcare providers, pharmacies, and distribution partners across various therapeutic areas including oncology, antiandrogens, antivirals, and cardiovascular medications.

flpharmaproducts.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
Pricing details1 tier
1B2B pharmaceutical product pricing through negotiated contracts
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed; subject to contract negotiations and government pricing regulations

flpharmaproducts.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Florida Pharmaceutical Products (FPP) develops, licenses, markets, and distributes FDA-approved generic prescription medications across multiple therapeutic areas including oncology, antivirals, cardiovascular, ophthalmic, and neurological treatments. The company also provides integrated pharmaceutical services such as regulatory compliance, contract manufacturing, distribution, government pricing, and supply chain management to manufacturing partners and healthcare buyers in the US market.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Multiple ANDA approvals achieved, with Abiraterone 500mg Tablets representing a $175+ million market opportunity
Product overview1 text field

Florida Pharmaceutical Products, LLC (FPP) is a generic pharmaceutical company offering a broad portfolio of FDA-approved generic prescription medications across multiple therapeutic areas. The product portfolio includes branded sub-lines: FPP Label products covering antiandrogens (Abiraterone Acetate), xanthine oxidase inhibitors (Allopurinol), ophthalmic solutions (Brimonidine Tartrate, Dorzolamide Timolol), tricyclic psychotherapeutic agents (Doxepin), antivirals (Entecavir, Valganciclovir), oncology treatments (Exemestane), diabetes medications (Glimepiride), anticonvulsants (Lacosamide), opioid withdrawal treatment (Lofexidine), and migraine therapy (Sumatriptan); and Quinn Label acquired products including antivirals (Acyclovir), antispasmodics (Glycopyrrolate), antineoplastics (Mercaptopurine), ALS treatment (Riluzole), and antiretrovirals (Tenofovir). Beyond products, FPP provides integrated services including Research and Development, Business Development, Project Management, Sales and Marketing, Operations, Regulatory Compliance, Distribution, Financial Services, Government Pricing, and Contract Manufacturing. The company operates through various business models including Internal Development, Licensing, and Asset Acquisition, with a focus on bringing affordably priced generic medications from development to distribution.

Product and service17 records
1Abiraterone Acetate Tablets
CategoryGeneric Pharmaceutical Product
Description

Generic antiandrogen tablets available in 250mg and 500mg strengths, indicated for treatment of metastatic castration-resistant and high-risk castration-sensitive prostate cancer in combination with prednisone.

2Allopurinol Tablets USP
CategoryGeneric Pharmaceutical Product
Description

Generic xanthine oxidase inhibitor tablets in 100mg and 300mg strengths indicated for treatment of gout, kidney stones, and prevention of high uric acid levels in blood.

3Brimonidine Tartrate Ophthalmic Solution
CategoryGeneric Pharmaceutical Product
Description

Generic alpha adrenergic receptor agonist ophthalmic solution in 0.2% strength, used for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

4Dorzolamide Timolol Ophthalmic Solution
CategoryGeneric Pharmaceutical Product
Description

Generic topical carbonic anhydrase inhibitor/beta blocker combination ophthalmic solution (0.5%/2%) for treating increased eye pressure caused by glaucoma or ocular hypertension.

5Doxepin Hydrochloride Capsules
CategoryGeneric Pharmaceutical Product
Description

Generic tricyclic psychotherapeutic capsules in 10mg, 25mg, 50mg, 75mg, and 100mg strengths for treatment of psychoneurotic patients with depression and/or anxiety.

6Entecavir Tablets
CategoryGeneric Pharmaceutical Product
Description

Generic nucleoside analogue reverse transcriptase inhibitor tablets in 0.5mg and 1mg strengths for treatment of chronic hepatitis B virus infection.

7Exemestane Tablets
CategoryGeneric Pharmaceutical Product
Description

Generic aromatase inhibitor tablets in 25mg strength for treatment of advanced breast cancer in postmenopausal women.

8Glimepiride Tablets USP
CategoryGeneric Pharmaceutical Product
Description

Generic sulfonylurea tablets in 1mg, 2mg, and 4mg strengths used in management and treatment of type 2 diabetes mellitus.

9Lacosamide Tablets USP
CategoryGeneric Pharmaceutical Product
Description

Generic anticonvulsant tablets in 50mg, 100mg, 150mg, and 200mg strengths used to control partial onset seizures in adults and children 1 month of age and older.

10Lofexidine Tablets
CategoryGeneric Pharmaceutical Product
Description

Generic alpha-adrenergic agonist and antihypertensive tablets in 0.18mg strength indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.

11Sumatriptan Nasal Spray
CategoryGeneric Pharmaceutical Product
Description

Generic serotonin receptor agonist nasal spray in 20mg strength for treatment of symptoms of migraine headache and cluster headache.

12Valganciclovir for Oral Solution
CategoryGeneric Pharmaceutical Product
Description

Generic antiviral oral solution in 50mg/mL strength used to treat and prevent cytomegalovirus (CMV) infections of the eye and body.

13Quinn Label - Tenofovir Disoproxil Fumarate Tablets
CategoryGeneric Pharmaceutical Product
Description

Generic antiretroviral tablets in 300mg strength indicated in combination with other antiretroviral agents for management of HIV-1 infection and treatment of chronic hepatitis B. Distributed under the Quinn Label.

14Quinn Label - Riluzole Tablets
CategoryGeneric Pharmaceutical Product
Description

Generic benzothiazole tablets in 50mg strength indicated for treatment of patients with amyotrophic lateral sclerosis (ALS). Sold under Quinn Label in the US.

15Quinn Label - Acyclovir Capsule
CategoryGeneric Pharmaceutical Product
Description

Generic antiviral/synthetic nucleoside analogue capsules in 200mg strength for treatment of infections caused by herpes viruses including genital herpes, cold sores, shingles, and chicken pox. Distributed under Quinn Label.

16Quinn Label - Glycopyrrolate Tablets
CategoryGeneric Pharmaceutical Product
Description

Generic antispasmodic/anticholinergic tablets in 1mg and 2mg strengths used as adjunct in peptic ulcer disorders and to diminish secretions. Distributed under Quinn Label.

17Quinn Label - Mercaptopurine Tablets
CategoryGeneric Pharmaceutical Product
Description

Generic antineoplastic/antimetabolite tablets in 50mg strength for maintenance therapy of acute lymphatic leukemia as part of a combination regimen; also for Crohn's disease and ulcerative colitis. Distributed under Quinn Label.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-20
Description

ONConcept developed Abiraterone 500mg Tablets ANDA generic for Zytiga. FPP manages US sales, marketing, and distribution. ONConcept is a strategic collaboration between Bluepharma (Portugal), Helm (Germany), and Welding (Germany) for oncology products. The product has peak sales exceeding $600 million with current generic sales of $175+ million.

2Standard Chem. & Pharm. Co., Ltd
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-09-30
Description

Licensing, supply, and distribution agreement for approved ANDA for Riluzole Tablets developed by Standard and approved by FDA. Standard is one of the leading pharmaceutical companies in Taiwan, founded in 1967 and publicly held since 1995. The product has sales of approximately $5 million according to IQVIA.

flpharmaproducts.com
3Inventia Healthcare Limited
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-04-01
Description

Licensing, supply, and distribution agreement for ANDA developed by Inventia, recently approved by FDA. Inventia is headquartered in Mumbai, India with marketing partners across 28 countries for niche generic oral solid products. The product has sales of approximately $125 million according to IQVIA.

flpharmaproducts.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-10-16
Description

Licensing agreement for niche generic ANDA developed by Impopharma Canada Limited (affiliate of Ayrton Saunders Ltd.). FPP will sell and distribute the product upon FDA approval. The product has sales of approximately $70 million according to IQVIA with limited generic competition.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-03-15
Description

FPP manages sales, marketing, and distribution of Qilu's ANDA for Tenofovir 300mg Tablets in the US. Qilu is a leading vertically integrated pharmaceutical company in China. The product has current sales of $130 million according to IQVIA.

6Quinn Pharmaceuticals, LLC
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-02-04
Description

Strategic alliance combining FPP's implementation expertise and industry relationships with Quinn's label and distribution capabilities. Deal creates end-to-end solution from procurement to order fulfillment, capitalizing on opportunities from Asia for US distribution. In May 2020, FPP acquired certain assets of Quinn Pharmaceuticals.

flpharmaproducts.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-09
Description

Partnership for development and licensing of ANDA for a selective serotonin reuptake inhibitor (SSRI). Bluepharma develops the ANDA while FPP files with FDA and manages sales, marketing, and distribution. Bluepharma is a European pharmaceutical company based in Coimbra, Portugal.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in generic pharmaceuticals with massive U.S. generics operation including oncology, cardiovascular, and CNS. Competes with FPP in multiple target markets as a broad incumbent, not a direct niche-specialist peer.

TypeBroad incumbent
Description

Large U.S. generic prescription operation of India-based Aurobindo Pharma with broad ANDA portfolio, in-licensing, and nationwide distribution. Broader incumbent with overlapping therapeutic coverage but greater scale and vertical integration.

TypeBroad incumbent
Description

India-based multinational with significant U.S. generics business spanning multiple therapeutic areas including oncology and ophthalmology. Comparable international sourcing model and broad generic portfolio, though at substantially larger scale.

TypeDirect peer
Description

Privately-held U.S. generic Rx distributor and developer that in-licenses, develops, and distributes niche generic products across therapeutic categories. Closest direct comparable to FPP given overlapping model, shared alumni (multiple FPP executives previously at Breckenridge), and similar product breadth in niche generics.

5Sandoz (Novartis)
TypeBroad incumbent
Description

Global generics and biosimilars division of Novartis with deep U.S. presence across all major therapeutic categories. Broad incumbent peer; overlaps with FPP in oncology and CNS generics but operates at vastly greater scale.

6Indoco Remedies Ltd.
TypeOthers
Description

India-based publicly-listed pharmaceutical company identified as FPP's parent/group. Operates formulations manufacturing and international generics — directly comparable in therapeutic portfolio (including oncology, ophthalmology) and the originator of the pipeline that FPP distributes in the U.S.

TypeDirect peer
Description

U.S. subsidiary of India-based Zydus Cadila developing and commercializing generic prescription products across multiple therapeutic areas. Comparable niche-and-broad-generic portfolio strategy and India-origin sourcing model similar to FPP's international partnership approach.

TypeDirect peer
Description

U.S.-based generic pharmaceutical manufacturer and distributor with broad portfolio across therapeutic areas including oncology, cardiovascular, and CNS. Comparable to FPP in product breadth and distribution model though larger in manufacturing scale.

TypeDirect peer
Description

U.S. generics subsidiary of Hetero Labs focusing on development, licensing, and distribution of niche generic prescription products across multiple therapeutic areas. Matches FPP's niche-generic, partnership-led, distribution-focused business model closely.

TypeDirect peer
Description

U.S. specialty generics company focused on niche, limited-competition generic prescription products across oncology, anti-infectives, and other therapeutic areas. Highly comparable business model: ANDA development, in-licensing, and specialty distribution.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Florida Pharmaceutical Products

Generic Pharmaceuticalsflpharmaproducts.com

Florida Pharmaceutical Products is a Boca Raton, FL-based generic pharmaceutical developer and distributor that in-licenses, develops, and markets FDA-approved generic prescription drugs across 10-plus therapeutic areas to US retail pharmacies, healthcare providers, and institutional buyers via a sales-led B2B distribution model.

What Florida Pharmaceutical Products does

Florida Pharmaceutical Products, LLC (FPP) is a Boca Raton, Florida-based generic pharmaceutical company that develops, in-licenses, markets, and distributes FDA-approved generic prescription medications across 10+ therapeutic categories including oncology (Abiraterone, Exemestane, Mercaptopurine), antivirals (Tenofovir, Entecavir, Valganciclovir, Acyclovir), ALS (Riluzole), cardiovascular and ophthalmic agents, anticonvulsants (Lacosamide), and diabetes (Glimepiride). The company operates through three business models: organic ANDA development, in-licensing of ANDAs from international manufacturers, and asset acquisition — exemplified by the May 2020 purchase of Quinn Pharmaceuticals label assets. Its product surface is anchored by the FPP Label and the acquired Quinn Label product lines, with supply chain and manufacturing executed via 3PL partners and DSCSA-compliant packaging/labeling.

FPP was founded by Larry Runsdorf and is currently led by President Larry J. Lapila (a 35-year industry veteran). In May 2019 the company was acquired by Contract Pharmacal Corp. (CPC), a family-owned Hauppauge, NY-based pharmaceutical manufacturer with approximately 1,500 employees, and FPP is also identified as part of Indoco Remedies Ltd.'s group of companies. Capital and manufacturing capacity from CPC, combined with strategic alliances to Bluepharma (Portugal), Qilu Pharmaceutical (China), Inventia Healthcare (India), Standard Chem. & Pharm. (Taiwan), ONConcept (Europe), and Impopharma (Canada), provide FPP with cross-continental sourcing for both development-stage and FDA-approved generic candidates. The company filed its first internally developed ANDA in February 2020 (~$100M market opportunity per IQVIA) and achieved FDA approval of Abiraterone Acetate 500mg Tabs in September 2023 (generic of Zytiga, current generic market of $175M+).

FPP runs a sales-led, B2B distribution model targeting retail pharmacies, healthcare providers, and institutional buyers across the US market, with pricing executed through multi-year negotiated contracts and subject to federal/state government pricing programs. Revenue is generated through product sales plus licensing/royalty arrangements with manufacturing partners, with FPP providing order-to-cash services including chargeback processing, rebates, and gross-to-net accounting under tight DSCSA-compliance governance. The customer base is US-only and distributed across the healthcare system, with no public revenue disclosure available in the source material.

Florida Pharmaceutical Products firmographics

Firmographics
Name
Florida Pharmaceutical Products
Legal name
Florida Pharmaceutical Products, LLC
Website
https://flpharmaproducts.com
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
Florida Pharmaceutical Products is a Boca Raton, FL-based generic pharmaceutical developer and distributor that in-licenses, develops, and markets FDA-approved generic prescription drugs across 10-plus therapeutic areas to US retail pharmacies, healthcare providers, and institutional buyers via a sales-led B2B distribution model.
Ownership category
akta.pro rank

Florida Pharmaceutical Products industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Generic pharmaceuticals
  • Prescription medications
  • ANDA development
  • Pharmaceutical distribution
  • Generic drug licensing

Where Florida Pharmaceutical Products is headquartered

Location

Headquarters

HQ city
Boca Raton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Florida Pharmaceutical Products business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Generic Pharmaceutical Sales: FPP generates revenue through the development, licensing, sales, marketing, and distribution of generic pharmaceutical products. Revenue is derived from product sales to healthcare providers, pharmacies, and distribution partners across various therapeutic areas including oncology, antiandrogens, antivirals, and cardiovascular medications.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B pharmaceutical product pricing through negotiated contracts

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Florida Pharmaceutical Products product offering

Product offering

Core offering

Florida Pharmaceutical Products (FPP) develops, licenses, markets, and distributes FDA-approved generic prescription medications across multiple therapeutic areas including oncology, antivirals, cardiovascular, ophthalmic, and neurological treatments. The company also provides integrated pharmaceutical services such as regulatory compliance, contract manufacturing, distribution, government pricing, and supply chain management to manufacturing partners and healthcare buyers in the US market.

Product overview

Florida Pharmaceutical Products, LLC (FPP) is a generic pharmaceutical company offering a broad portfolio of FDA-approved generic prescription medications across multiple therapeutic areas. The product portfolio includes branded sub-lines: FPP Label products covering antiandrogens (Abiraterone Acetate), xanthine oxidase inhibitors (Allopurinol), ophthalmic solutions (Brimonidine Tartrate, Dorzolamide Timolol), tricyclic psychotherapeutic agents (Doxepin), antivirals (Entecavir, Valganciclovir), oncology treatments (Exemestane), diabetes medications (Glimepiride), anticonvulsants (Lacosamide), opioid withdrawal treatment (Lofexidine), and migraine therapy (Sumatriptan); and Quinn Label acquired products including antivirals (Acyclovir), antispasmodics (Glycopyrrolate), antineoplastics (Mercaptopurine), ALS treatment (Riluzole), and antiretrovirals (Tenofovir). Beyond products, FPP provides integrated services including Research and Development, Business Development, Project Management, Sales and Marketing, Operations, Regulatory Compliance, Distribution, Financial Services, Government Pricing, and Contract Manufacturing. The company operates through various business models including Internal Development, Licensing, and Asset Acquisition, with a focus on bringing affordably priced generic medications from development to distribution.

Differentiator

Problem solved

Functional benefit

Products and services

  • Abiraterone Acetate Tablets Generic antiandrogen tablets available in 250mg and 500mg strengths, indicated for treatment of metastatic castration-resistant and high-risk castration-sensitive prostate cancer in combination with prednisone.
  • Allopurinol Tablets USP Generic xanthine oxidase inhibitor tablets in 100mg and 300mg strengths indicated for treatment of gout, kidney stones, and prevention of high uric acid levels in blood.
  • Brimonidine Tartrate Ophthalmic Solution Generic alpha adrenergic receptor agonist ophthalmic solution in 0.2% strength, used for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
  • Dorzolamide Timolol Ophthalmic Solution Generic topical carbonic anhydrase inhibitor/beta blocker combination ophthalmic solution (0.5%/2%) for treating increased eye pressure caused by glaucoma or ocular hypertension.
  • Doxepin Hydrochloride Capsules Generic tricyclic psychotherapeutic capsules in 10mg, 25mg, 50mg, 75mg, and 100mg strengths for treatment of psychoneurotic patients with depression and/or anxiety.
  • Entecavir Tablets Generic nucleoside analogue reverse transcriptase inhibitor tablets in 0.5mg and 1mg strengths for treatment of chronic hepatitis B virus infection.
  • Exemestane Tablets Generic aromatase inhibitor tablets in 25mg strength for treatment of advanced breast cancer in postmenopausal women.
  • Glimepiride Tablets USP Generic sulfonylurea tablets in 1mg, 2mg, and 4mg strengths used in management and treatment of type 2 diabetes mellitus.
  • Lacosamide Tablets USP Generic anticonvulsant tablets in 50mg, 100mg, 150mg, and 200mg strengths used to control partial onset seizures in adults and children 1 month of age and older.
  • Lofexidine Tablets Generic alpha-adrenergic agonist and antihypertensive tablets in 0.18mg strength indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
  • Sumatriptan Nasal Spray Generic serotonin receptor agonist nasal spray in 20mg strength for treatment of symptoms of migraine headache and cluster headache.
  • Valganciclovir for Oral Solution Generic antiviral oral solution in 50mg/mL strength used to treat and prevent cytomegalovirus (CMV) infections of the eye and body.
  • Quinn Label - Tenofovir Disoproxil Fumarate Tablets Generic antiretroviral tablets in 300mg strength indicated in combination with other antiretroviral agents for management of HIV-1 infection and treatment of chronic hepatitis B. Distributed under the Quinn Label.
  • Quinn Label - Riluzole Tablets Generic benzothiazole tablets in 50mg strength indicated for treatment of patients with amyotrophic lateral sclerosis (ALS). Sold under Quinn Label in the US.
  • Quinn Label - Acyclovir Capsule Generic antiviral/synthetic nucleoside analogue capsules in 200mg strength for treatment of infections caused by herpes viruses including genital herpes, cold sores, shingles, and chicken pox. Distributed under Quinn Label.
  • Quinn Label - Glycopyrrolate Tablets Generic antispasmodic/anticholinergic tablets in 1mg and 2mg strengths used as adjunct in peptic ulcer disorders and to diminish secretions. Distributed under Quinn Label.
  • Quinn Label - Mercaptopurine Tablets Generic antineoplastic/antimetabolite tablets in 50mg strength for maintenance therapy of acute lymphatic leukemia as part of a combination regimen; also for Crohn's disease and ulcerative colitis. Distributed under Quinn Label.

Quantifiable outcome

  • Multiple ANDA approvals achieved, with Abiraterone 500mg Tablets representing a $175+ million market opportunity

Companies that use Florida Pharmaceutical Products

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Florida Pharmaceutical Products technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Florida Pharmaceutical Products partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core.

  • ONConcept (Bluepharma/Helm/Welding partnership)coreStrategic or Co-development Partner · 20 September 2023ONConcept developed Abiraterone 500mg Tablets ANDA generic for Zytiga. FPP manages US sales, marketing, and distribution. ONConcept is a strategic collaboration between Bluepharma (Portugal), Helm (Germany), and Welding (Germany) for oncology products. The product has peak sales exceeding $600 million with current generic sales of $175+ million.
  • Standard Chem. & Pharm. Co., LtdcoreOEM/ Whitelabel/ Licensing Partner · 30 September 2020Licensing, supply, and distribution agreement for approved ANDA for Riluzole Tablets developed by Standard and approved by FDA. Standard is one of the leading pharmaceutical companies in Taiwan, founded in 1967 and publicly held since 1995. The product has sales of approximately $5 million according to IQVIA.
  • Inventia Healthcare LimitedcoreOEM/ Whitelabel/ Licensing Partner · 1 April 2020Licensing, supply, and distribution agreement for ANDA developed by Inventia, recently approved by FDA. Inventia is headquartered in Mumbai, India with marketing partners across 28 countries for niche generic oral solid products. The product has sales of approximately $125 million according to IQVIA.
  • Impopharma Canada Limited / Ayrton Saunders Ltd.coreOEM/ Whitelabel/ Licensing Partner · 16 October 2019Licensing agreement for niche generic ANDA developed by Impopharma Canada Limited (affiliate of Ayrton Saunders Ltd.). FPP will sell and distribute the product upon FDA approval. The product has sales of approximately $70 million according to IQVIA with limited generic competition.
  • Qilu Pharmaceutical Co., Ltd.coreOEM/ Whitelabel/ Licensing Partner · 15 March 2019FPP manages sales, marketing, and distribution of Qilu's ANDA for Tenofovir 300mg Tablets in the US. Qilu is a leading vertically integrated pharmaceutical company in China. The product has current sales of $130 million according to IQVIA.
  • Quinn Pharmaceuticals, LLCcoreStrategic or Co-development Partner · 4 February 2019Strategic alliance combining FPP's implementation expertise and industry relationships with Quinn's label and distribution capabilities. Deal creates end-to-end solution from procurement to order fulfillment, capitalizing on opportunities from Asia for US distribution. In May 2020, FPP acquired certain assets of Quinn Pharmaceuticals.
  • Bluepharma Indústria Farmacêutica, S.A.coreStrategic or Co-development Partner · 9 January 2019Partnership for development and licensing of ANDA for a selective serotonin reuptake inhibitor (SSRI). Bluepharma develops the ANDA while FPP files with FDA and manages sales, marketing, and distribution. Bluepharma is a European pharmaceutical company based in Coimbra, Portugal.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Florida Pharmaceutical Products competitors and assessment

Company assessment

Broad incumbents

  • Teva Pharmaceutical Industries: Global leader in generic pharmaceuticals with massive U.S. generics operation including oncology, cardiovascular, and CNS. Competes with FPP in multiple target markets as a broad incumbent, not a direct niche-specialist peer.
  • Aurobindo Pharma USA: Large U.S. generic prescription operation of India-based Aurobindo Pharma with broad ANDA portfolio, in-licensing, and nationwide distribution. Broader incumbent with overlapping therapeutic coverage but greater scale and vertical integration.
  • Dr. Reddy's Laboratories: India-based multinational with significant U.S. generics business spanning multiple therapeutic areas including oncology and ophthalmology. Comparable international sourcing model and broad generic portfolio, though at substantially larger scale.
  • Sandoz (Novartis): Global generics and biosimilars division of Novartis with deep U.S. presence across all major therapeutic categories. Broad incumbent peer; overlaps with FPP in oncology and CNS generics but operates at vastly greater scale.

Direct peers

  • Breckenridge Pharmaceutical: Privately-held U.S. generic Rx distributor and developer that in-licenses, develops, and distributes niche generic products across therapeutic categories. Closest direct comparable to FPP given overlapping model, shared alumni (multiple FPP executives previously at Breckenridge), and similar product breadth in niche generics.
  • Zydus Pharmaceuticals USA: U.S. subsidiary of India-based Zydus Cadila developing and commercializing generic prescription products across multiple therapeutic areas. Comparable niche-and-broad-generic portfolio strategy and India-origin sourcing model similar to FPP's international partnership approach.
  • Lannett Company: U.S.-based generic pharmaceutical manufacturer and distributor with broad portfolio across therapeutic areas including oncology, cardiovascular, and CNS. Comparable to FPP in product breadth and distribution model though larger in manufacturing scale.
  • Camber Pharmaceuticals: U.S. generics subsidiary of Hetero Labs focusing on development, licensing, and distribution of niche generic prescription products across multiple therapeutic areas. Matches FPP's niche-generic, partnership-led, distribution-focused business model closely.
  • ANI Pharmaceuticals: U.S. specialty generics company focused on niche, limited-competition generic prescription products across oncology, anti-infectives, and other therapeutic areas. Highly comparable business model: ANDA development, in-licensing, and specialty distribution.

Others

  • Indoco Remedies Ltd. India-based publicly-listed pharmaceutical company identified as FPP's parent/group. Operates formulations manufacturing and international generics — directly comparable in therapeutic portfolio (including oncology, ophthalmology) and the originator of the pipeline that FPP distributes in the U.S.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Florida Pharmaceutical Products social profiles

Digital presence

Florida Pharmaceutical Products compliance and trust

Trust signal

Compliance1 record

Florida Pharmaceutical Products financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Florida Pharmaceutical Products leadership team

Management profile

Number of profiles

Profiles7 records

Florida Pharmaceutical Products subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Florida Pharmaceutical Products funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Florida Pharmaceutical Products M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Florida Pharmaceutical Products

What does Florida Pharmaceutical Products do?

Florida Pharmaceutical Products (FPP) develops, licenses, markets, and distributes FDA-approved generic prescription medications across multiple therapeutic areas including oncology, antivirals, cardiovascular, ophthalmic, and neurological treatments. The company also provides integrated pharmaceutical services such as regulatory compliance, contract manufacturing, distribution, government pricing, and supply chain management to manufacturing partners and healthcare buyers in the US market.

Is Florida Pharmaceutical Products a public or private company?

Florida Pharmaceutical Products is a private company. It is classified as corporate owned and is currently operating.

When was Florida Pharmaceutical Products founded?

Florida Pharmaceutical Products was founded in -1. It employs 1 to 10 people.

Where is Florida Pharmaceutical Products based?

Florida Pharmaceutical Products is headquartered in Boca Raton, United States, in the North America region.

How does Florida Pharmaceutical Products make money?

One revenue line is on record: generic Pharmaceutical Sales.

Who are Florida Pharmaceutical Products's main competitors?

Broad incumbents on record are Teva Pharmaceutical Industries, Aurobindo Pharma USA, Dr. Reddy's Laboratories and Sandoz (Novartis). Direct peers are Breckenridge Pharmaceutical, Zydus Pharmaceuticals USA, Lannett Company, Camber Pharmaceuticals and ANI Pharmaceuticals. Indoco Remedies Ltd. is listed as an others.

Does Florida Pharmaceutical Products have an API?

No public API is recorded for Florida Pharmaceutical Products.

What industry is Florida Pharmaceutical Products in?

Florida Pharmaceutical Products's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals